Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters
REHOVOT, Israel , and BRIDGEWATER, N.J. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Pricing of its Follow-on Offering of Ordinary Shares
REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Proposed Follow-on Offering of Ordinary Shares
REHOVOT, Israel , and BRIDGEWATER, N.J. , Sept. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
FMX101 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Tomorrow at 8:00 a.m. EDT REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd.
Toggle Summary Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Rehovot, Israel, August 8, 2018 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today its financial results for the second quarter and six months ended June 30, 2018.
Toggle Summary Foamix Pharmaceuticals to Announce Second Quarter Financial Results on August 8
Rehovot, Israel, and Bridgewater, NJ – August 1st, 2018 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report financial results for the three and six-month periods ended June 30, 2018, on Wednesday, August 8 after the markets close.
Toggle Summary Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103
Top-line results expected early Q4 2018 Rehovot, Israel, and Bridgewater, NJ – June 27, 2018  – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology,
Toggle Summary Foamix Pharmaceuticals to Participate in the Cantor Dermatology & Aesthetics Summit
REHOVOT, Israel and BRIDGEWATER, N.J. , June 14, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that
Toggle Summary Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update
Conference Call and Webcast on Wednesday, May 9 at 8:30am Eastern Time REHOVOT, Israel , May 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary
Toggle Summary Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101
Top-line Results Expected in the Third Quarter of 2018 REHOVOT, Israel , and BRIDGEWATER, N.J. , May 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to
Toggle Summary Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for May 9
REHOVOT, Israel , and BRIDGEWATER, N.J. , April 24, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces $16 Million Investment by OrbiMed
REHOVOT, Israel and BRIDGEWATER, N.J. , April 16, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2018
REHOVOT, Israel , and BRIDGEWATER, N.J. , March 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference
REHOVOT, Israel , and BRIDGEWATER, N.J. , March 06, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate Update
Long Term Open Label Clinical Results Confirm That FMX101 Appears to be Safe and Well Tolerated; Continued Improvement of Treatment Effect Demonstrated at 52 Weeks Conference Call and Webcast on Wednesday, February 28, 2018 at 8:30am Eastern REHOVOT, Israel , Feb.
Toggle Summary Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call & Webcast Scheduled for February 28
REHOVOT, Israel , and BRIDGEWATER, N.J. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year
Long Term Data on FMX-101 in Moderate-to-Severe Acne to be Presented at Winter Clinical Dermatology Conference ( January 12 th -17 th ) REHOVOT, Israel and BRIDGEWATER, N.J. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty
Toggle Summary Foamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals
REHOVOT, Israel and BRIDGEWATER, N.J. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Reports Third Quarter 2017 Financial Results and Provides Business Update
Conference Call and Webcast on Wednesday, November 15, 2017 at 8:30am Eastern / 5:30am Pacific REHOVOT, Israel , Nov. 15, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on
Toggle Summary Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 15, 2017
REHOVOT, Israel , and BRIDGEWATER, N.J. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today